Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Connecticut for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Connecticut only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Connecticut (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Yousong Wang (NPI 1023253200)

Field	Value
Entity Type	Individual
Organization	Yousong Wang
Address	40 Dale Rd Ste 203
City	Avon
State	CT
ZIP	06001
Taxonomy	General Practice Physician
NPI Enumerated	December 2, 2008

Payer Source	Total Paid
Medicare	$861.3K
Medicaid	$0

Key Findings

This provider is effectively a Medicare-only biller: Total Medicare revenue is $861.3K and there is no Medicaid billing on file. That single‑payer concentration means the provider’s financial footprint in public programs is entirely driven by Medicare activity rather than a mixed payer strategy.

Revenue is extremely concentrated in a very small set of drug administration codes: the precomputed top 3 Medicare codes by revenue account for 91.3% of this provider's total Medicare revenue. The two dominant J‑codes are J1602 ($578.1K, 68.0% of Medicare revenue) and J0717 ($172K, 20.2%), indicating the bulk of dollars come from provision of specific injectable biologic therapies.

Service-line profile points to an infusion/biologics focus rather than routine primary care: high revenues on J1602 and J0717 and elevated administration codes such as 96365 (396 claims, $20.6K revenue) and add-on infusion code 96415 (101 claims, $2.4K revenue) show the practice administers intravenous biologics and infusion therapies alongside E&M visits. The presence of chemotherapy procedure code 96413 (175 claims, $19.6K revenue) further supports an infusion-capable operation rather than only office‑based visits.

Competitive standing on the top biologic is nationally strong: J1602 ranks #33 of 1041 providers nationally (97th percentile) and is described as notably above typical national volume, so the provider is a high-volume participant for this specific drug nationally. By contrast, J0717 ranks #476 of 848 providers (44th percentile) and is labeled typical/unremarkable, indicating the provider is a major player for golimumab (J1602) but only an average participant for certolizumab (J0717).

E&M activity is present but not a major revenue driver: 99214 generated $26.1K (3.1% of Medicare revenue) across 266 claims and ranks #114959 of 479517 providers (76th percentile), reflecting a moderate level of office visit volume compared with peers. This suggests that while the provider performs evaluation and management services, those visits are secondary to infusion/biologic revenue.

There are mixed signals among other administration and drug codes that temper the concentration observation: 96365 ranks #590 of 8873 (93th percentile) and is labeled typical/unremarkable, showing relatively high infusion administration volume compared to many peers, while J0897 (denosumab) ranks #8823 of 10057 (10th percentile) and is labeled typical/unremarkable, indicating low participation in that specific drug. These rank contrasts show the provider is selective in the biologics and infusion products it bills at scale.

Tenure and credentialing are long-established: the NPI was enumerated on 2008-12-02 (~18 years ago), which indicates sustained enrollment in Medicare for roughly two decades and supports the likelihood that current billing patterns reflect an established service mix rather than a very recent practice change.

Concentration risk for revenue is material from a payer and operational perspective: with $578.1K from J1602 alone (68.0% of Medicare revenue) and the top 3 codes totaling 91.3% of Medicare revenue, changes in Medicare reimbursement policy, drug pricing, or utilization guidance for these specific J‑codes could meaningfully affect the provider’s Medicare revenue stream.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

13 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J1602	Injection, golimumab, 1 mg, for intravenous use	57,810	$10	$578.1K
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	43,000	$1	$172K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	270	$100	$26.1K
96365	The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease.	400	$50	$20.6K
J0897	Injection, denosumab, 1 mg	1,080	$20	$20.5K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	180	$110	$19.6K
99204	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider…	30	$140	$4.7K
96372	A therapeutic, prophylactic, or diagnostic substance (a fluid, a drug, etc.) is injected via intramuscular or subcutaneous route into the patient's body. The procedure is performed by the physician…	240	$10	$2.9K
96415	In this add on procedure, the provider continues administration of a chemotherapy drug into a vein using an infusion technique. He uses this code to report each additional hour of infusion beyond the…	100	$20	$2.4K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	30	$70	$1.9K

Showing 1–10 of 13

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 13 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Connecticut Distribution

Yousong Wang — 2 of 13 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Connecticut

Full comparison — all codes billed, vs. state median

13 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J1602	1	10	10,200	$10	$202.9K
J0717	3	10	30,430	$1	$130K
J0897	86	100	2,700	$20	$66.4K
99214	1,133	6,480	90	$90	$14.2K
96413	14	50	110	$110	$13.6K
99213	5,149	6,440	70	$60	$8.1K
96365	2	60	50	$50	$4.7K
99204	1,006	2,660	30	$120	$4.6K
96367	16	20	60	$20	$3.2K
36415	372	570	60	$10	$1.7K

Showing 1–10 of 13

Related Providers

Other providers that share a Tax Identification Number (TIN) with Yousong Wang, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Starling Physicians, PLLC	CT	Internal Medicine Physician	$0	$38.1M
Starling Physicians, PLLC	CT	Clinical Medical Laboratory	$809.9K	$4.4M
Edward Fitzpatrick	CT	Ophthalmology Physician	$757.6K	$0
Nauman Piracha	CT	Hospitalist Physician	$489.5K	$104.3K
Stephen Firshein	CT	Hematology & Oncology Physician	$587.4K	$0
Sakshi Kapur	NJ	Internal Medicine Physician	$391.6K	$0
Matthew Brown	CT	Surgery Physician	$355.3K	$0
Katherine Davoren	RI	Nephrology Physician	$82.9K	$238.5K
Lawrence Giove	CT	Hematology & Oncology Physician	$302.2K	$0
Michael Lawlor	CT	Infectious Disease Physician	$299.8K	$0

Nearby Providers

Other providers in the same ZIP code as Yousong Wang, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Hartford Healthcare Urgent Care Centers, LLC	CT	Urgent Care Clinic/Center	$0	$23.4M
Behavioral Health Consulting Services LLC	CT	Professional Counselor	$0	$4.9M
Harvest Healthcare LLC	CT	Clinical Social Worker	$0	$2.5M
Michael Shiembob	CT	Optometrist	$8.7K	$1.7M
Creative Development, LLC	CT	Specialist	$0	$1.2M
Sadaf Waqar	CT	Dermatology Physician	$652.8K	$0
Evan Schiff	CT	Internal Medicine Physician	$204K	$0
Savitha Chandramohan	CT	Psychiatric/Mental Health Nurse Practitioner	$170.1K	$0
Connecticut Cvs Pharmacy, L.L.C.	CT	Pharmacy	$164.9K	$0
Yvette Bailey	CT	Diagnostic Radiology Physician	$100K	$0

Yousong Wang — Billing Profile & Reimbursement Data

Sign up for Yousong Wang — Billing Profile & Reimbursement Data policy alerts

Yousong Wang — Billing Profile & Reimbursement Data

Sign up for Yousong Wang — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References